Recent advances in COPD: Pathophysiology, respiratory physiology and clinical aspects, including comorbidities

European Respiratory Review

Volumn 18, Issue 114, 2009, Pages 198-212

  Bourdin, A ^a   Burgel, P R ^b   Chanez, P ^d   Garcia, G ^e   Perez, T ^f   Roche, N ^c  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b Cochin Hospital ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IPRATROPIUM BROMIDE; NITROGEN; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR; SALBUTAMOL; SALMETEROL;

AIRWAY OBSTRUCTION; ANEMIA; BREATHING MUSCLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COUGHING; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DYSLIPIDEMIA; DYSPNEA; EXERCISE; EXERCISE TEST; EXPIRATORY FLOW; GAS EXCHANGE; HEALTH STATUS; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG MECHANICS; MALNUTRITION; MUSCLE EXERCISE; NITROGEN WASHOUT; OSCILLATION; OSTEOPENIA; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RESPIRATORY FUNCTION; REVIEW; SLEEP APNEA SYNDROME; SPIROMETRY; SPUTUM; THERAPY EFFECT;

CHRONIC DISEASE; EXERCISE TEST; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION; RESPIRATORY MECHANICS; SPIROMETRY;

EID: 73449093870     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00005509     Document Type: Review

References (134)

1. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev 2009; 18: 213-221.
2. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8: 183-192.
3. Willemse BW, ten Hacken NH, Rutgers B, et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26: 835-845.
4. Hogg J. Peripheral lung remodelling in asthma and chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 893-894.
5. Battaglia S, Mauad T, van Schadewijk AM, et al. Differential distribution of inflammatory cells in large and small airways in smokers. J Clin Pathol 2007; 60: 907-911.
6. Sturton G, Persson C, Barnes PJ. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol Sci 2008; 29: 340-345.
7. Lapperre TS, Willems LN, Timens W, et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 2007; 131: 53-59.
8. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006; 533: 222-239.
9. Maestrelli P, Paska C, Saetta M, et al. Decreased haemoxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J 2003; 21: 971-976.
10. Slebos DJ, Kerstjens HA, Rutgers SR, et al. Haem oxygenase-1 expression is diminished in alveolar macrophages of patients with COPD. Eur Respir J 2004; 23: 652-653.
11. Goven D, Boutten A, Lecon-Malas V, et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax 2008; 63: 916-924.
12. Boschetto P, Miniati M, Miotto D, et al. Predominant emphysema phenotype in chronic obstructive pulmonary. Eur Respir J 2003; 21: 450-454.
13. Vignola AM, Paganin F, Capieu L, et al. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004; 24: 910-917.
14. Baraldo S, Bazzan E, Zanin ME, et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007; 132: 1733-1740.
15. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546-3556.
16. Fujimoto K, Yasuo M, Urushibata K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005; 25: 640-646.
17. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008; 31: 62-69.
18. Mortaz E, Lazar Z, Koenderman L, et al. Cigarette smoke attenuates the production of cytokines by human plasmacytoid dendritic cells and enhances the release of IL-8 in response to TLR-9 stimulation. Respir Res 2009; 10: 47.
19. Gosman MM, Willemse BW, Jansen DF, et al. Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J 2006; 27: 60-64.
20. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
21. Majori M, Corradi M, Caminati A, et al. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J Allergy Clin Immunol 1999; 103: 458-462.
22. Bruno A, Chanez P, Chiappara G, et al. Does leptin play a cytokine-like role within the airways of COPD patients? Eur Respir J 2005; 26: 398-405.
23. Baraldo S, Saetta M. To reg or not to reg: that is the question in COPD. Eur Respir J 2008; 31: 486-488.
24. Brusselle GG, Demoor T, Bracke KR, et al. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009; 34: 219-230.
25. Bourdin A, Neveu D, Vachier I, et al. Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol 2007; 119: 1367-1374.
26. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J 2007; 30: 134-155.
27. Schermer TR, Smeele IJ, Thoonen BP, et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008; 32: 945-952.
28. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
29. Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1/FVC ratio below the fifth percentile, not <70%. Chest 2007; 131: 349-355.
30. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63: 1046-1051.
31. Cerveri I, Corsico AG, Accordini S, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63: 1040-1045.
32. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742-750.
33. Cote CG, Casanova C, Marin JM, et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008; 31: 571-578.
34. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158: 1384-1387.
35. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999; 14: 270-274.
36. Casanova C, Cote C, Marin JM, et al. Distance and oxygen desaturation during the 6-min walk test as predictors of longterm mortality in patients with COPD. Chest 2008; 134: 746-752.
37. Redelmeier DA, Bayoumi AM, Goldstein RS, et al. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-1282.
38. Puhan MA, Mador MJ, Held U, et al. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008; 32: 637-643.
39. Singh SJ, Jones PW, Evans R, et al. Minimum clinically important improvement for the incremental shuttle walking test. Thorax 2008; 63: 775-777.
40. Brouillard C, Pepin V, Milot J, et al. Endurance shuttle walking test: responsiveness to salmeterol in COPD. Eur Respir J 2008; 31: 579-584.
41. O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol 2008; 105: 753-755.
42. Ofir D, Laveneziana P, Webb KA, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 622-629.
43. Macklem PT. Circulatory effects of expiratory flow-limited exercise, dynamic hyperinlation and expiratory muscle pressure. Eur Respir Rev 2006; 15: 80-84.
44. Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J 2008; 32: 1275-1282.
45. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 591-597.
46. Chiappa GR, Borghi-Silva A, Ferreira LF, et al. Kinetics of muscle deoxygenation are accelerated at the onset of heavy-intensity exercise in patients with COPD: relationship to central cardiovascular dynamics. J Appl Physiol 2008; 104: 1341-1350.
47. Chiappa GR, Queiroga Jr F, Meda E, et al. Heliox improves oxygen delivery and utilization during dynamic exercise in patients with COPD. Am J Respir Crit Care Med 2009; 179: 1004-1010.
48. Dellaca RL, Santus P, Aliverti A, et al. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J 2004; 23: 232-240.
49. Dellaca RL, Duffy N, Pompilio PP, et al. Expiratory flow limitation detected by forced oscillation and negative expiratory pressure. Eur Respir J 2007; 29: 363-374.
50. Kubota M, Shirai G, Nakamori T, et al. Low frequency oscillometry parameters in COPD patients are less variable during inspiration than during expiration. Respir Physiol Neurobiol 2009; 166: 73-79.
51. Dellaca RL, Pompilio PP, Walker PP, et al. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009; 33: 1329-1337.
52. Di Mango AM, Lopes AJ, Jansen JM, et al. Changes in respiratory mechanics with increasing degrees of airway obstruction in COPD: detection by forced oscillation technique. Respir Med 2006; 100: 399-410.
53. Johnson MK, Birch M, Carter R, et al. Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry. Thorax 2007; 62: 299-306.
54. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
55. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281.
56. Buist AS, Vollmer WM, Johnson LR, et al. Does the single-breath N2 test identify the smoker who will develop chronic airflow limitation? Am Rev Respir Dis 1988; 137: 293-301.
57. Stanescu D, Sanna A, Veriter C, et al. Identification of smokers susceptible to development of chronic airflow limitation: a 13-year follow-up. Chest 1998; 114: 416-425.
58. Lapperre TS, Willems LN, Timens W, et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 2007; 131: 53-59.
59. Verbanck S, Schuermans D, Van Muylem A, et al. Conductive and acinar lung-zone contributions to ventilation inhomogeneity in COPD. Am J Respir Crit Care Med 1998; 157: 1573-1577.
60. Verbanck S, Schuermans D, Meysman M, et al. Noninvasive assessment of airway alterations in smokers: the small airways revisited. Am J Respir Crit Care Med 2004; 170: 414-419.
61. Hill K, Jenkins SC, Philippe DL, et al. High-intensity inspiratory muscle training in COPD. Eur Respir J 2006; 27: 1119-1128.
62. Hill K, Jenkins SC, Philippe DL, et al. Comparison of incremental and constant load tests of inspiratory muscle endurance in COPD. Eur Respir J 2007; 30: 479-486.
63. Decramer M. Response of the respiratory muscles to rehabilitation in COPD. J Appl Physiol 2009; 107: 971-976.
64. Ottenheijm CA, Heunks LM, Dekhuijzen PN. Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: toward a pathophysiological concept. Am J Respir Crit Care Med 2007; 175: 1233-1240.
65. van Hees HW, Dekhuijzen PN, Heunks LM. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 41-47.
66. Luo YM, Lyall RA, Lou Harris M, et al. Quantification of the esophageal diaphragm electromyogram with magnetic phrenic nerve stimulation. Am J Respir Crit Care Med 1999; 160: 1629-1634.
67. Luo YM, Hart N, Mustfa N, et al. Effect of diaphragm fatigue on neural respiratory drive. J Appl Physiol 2001; 90: 1691-1699.
68. Jolley CJ, Luo YM, Steier J, et al. Neural respiratory drive in healthy subjects and in COPD. Eur Respir J 2009; 33: 289-297.
69. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224-1238.
70. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: Suppl. 2, 398S-401S.
71. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1204-1213.
72. Foreman MG, DeMeo DL, Hersh CP, et al. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 2007; 30: 1124-1130.
73. Bourbeau J, Ford G, Zackon H, et al. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007; 30: 907-913.
74. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J COPD 2009; 4: 245-251.
75. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131: 696-704.
76. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29: 527-534.
77. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255.
78. Quint JK, Baghai-Ravary R, Donaldson GC, et al. Relationship between depression and exacerbations in COPD. Eur Respir J 2008; 32: 53-60.
79. Fletcher C, Peto R, Tinker C, et al. The Natural History of Chronic Bronchitis and Emphysema.Oxford,OxfordUniversity Press, 1976.
80. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-332.
81. Lindberg A, Eriksson B, Larsson LG, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006; 129: 879-885.
82. DeMeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax 2007; 62: 806-813.
83. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, et al. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005; 6: 98.
84. Pelkonen M, Notkola IL, Nissinen A, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middleaged rural men. Chest 2006; 130: 1129-1137.
85. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-982.
86. Seemungal TA, DonaldsonGC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
87. Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67: 495-501.
88. Crawford B, Monz B, Hohlfeld J, et al. Development and validation of a cough and sputum assessment questionnaire. Respir Med 2008; 102: 1545-1555.
89. Burgel PR, Nadel JA. Epidermal growth factor receptormediated innate immune responses and their roles in airway diseases. Eur Respir J 2008; 32: 1068-1081.
90. Breslin E, van der SC, Breukink S, et al. Perception of fatigue and quality of life in patients with COPD. Chest 1998; 114: 958-964.
91. Martin A, Rodriguez-Gonzalez Moro JM, Izquierdo JL, et al. Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish Study. Int J COPD 2008; 3: 683-692.
92. Izquierdo JL, Barcina C, Jimenez J, et al. Study of the burden on patients with chronic obstructive pulmonary disease. Int J Clin Pract 2009; 63: 87-97.
93. Geijer RM, Sachs AP, Verheij TJ, et al. Quality of life in smokers: focus on functional limitations rather than on lung function? Br J Gen Pract 2007; 57: 477-482.
94. de Torres JP, Casanova C, Hernandez C, et al. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health Qual Life Outcomes 2006; 4: 72.
95. de Torres JP, Casanova C, Montejo de Garcini A, et al. Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respir Res 2007; 8: 18.
96. Watz H, Waschki B, Meyer T, et al. Physical activity in patients with COPD. Eur Respir J 2009; 33: 262-272.
97. Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit CareMed 2008; 177: 743-751.
98. Pitta F, Takaki MY, Oliveira NH, et al. Relationship between pulmonary function and physical activity in daily life in patients with COPD. Respir Med 2008; 102: 1203-1207.
99. Garcia-Aymerich J, Serra I, Gomez FP, et al. Physical activity and clinical and functional status in COPD. Chest 2009; 136: 62-70.
100. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-778.
101. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med 2007; 175: 458-463.
102. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
103. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
104. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
105. Crisafulli E, Costi S, Luppi F, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487-492.
106. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797.
107. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173: 79-83.
108. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and females with obstructive airways disease. Am J Med 2003; 114: 10-14.
109. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
110. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986; 105: 503-507.
111. Antonelli-Incalzi R, Corsonello A, Pedone C, et al. Drawing impairment predicts mortality in severe COPD. Chest 2006; 130: 1687-1694.
112. Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167: 60-67.
113. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 2008; 178: 913-920.
114. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-355.
115. Charlson M, Charlson RE, Briggs W, et al. Can disease management target patients most likely to generate high costs? The impact of comorbidity. J Gen Intern Med 2007; 22: 464-469.
116. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70.
117. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-2011.
118. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
119. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
120. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
121. Johnston AK, Mannino DM, Hagan GW, et al. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63: 599-605.
122. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007; 132: 1932-1938.
123. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008; 178: 738-744.
124. Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med 2008; 14: 1023-1024.
125. Ohara T, Hirai T, Muro S, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008; 134: 1244-1249.
126. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
127. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
128. Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 301-305.
129. Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
130. Suissa S, Ernst P. Biases in the observational study of beta blockers in COPD. Thorax 2008; 63: 1026-1027.
131. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-799.
132. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
133. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
134. Celli B, Jones P, Vestbo J, et al. The multidimensional BOD: association with mortality in the TORCH trial. Eur Respir J 2008; 32: Suppl. 52, A384.